---
annotations:
- id: PW:0000624
  parent: disease pathway
  type: Pathway Ontology
  value: breast cancer pathway
- id: CL:0002326
  parent: animal cell
  type: Cell Type Ontology
  value: luminal epithelial cell of mammary gland
- id: PW:0000754
  parent: drug pathway
  type: Pathway Ontology
  value: drug pathway
- id: CL:0002327
  parent: animal cell
  type: Cell Type Ontology
  value: mammary gland epithelial cell
- id: DOID:1612
  parent: disease of cellular proliferation
  type: Disease Ontology
  value: breast cancer
authors:
- Eweitz
citedin: ''
communities: []
description: '"Trastuzumab and pertuzumab inhibit HER2 signaling by binding to the
  extracellular domain of HER2. Lapatinib, neratinib, tucatinib, and pyrotinib inhibit
  HER signaling by binding to the intracellular tyrosine kinase domain of the Her
  family members.".  Source: Figure F1, https://pmc.ncbi.nlm.nih.gov/articles/PMC9281252/.  Derived
  from PFOCR, https://pfocr.wikipathways.org/figures/PMC9281252__12032_2022_1749_Fig1_HTML.html.'
last-edited: 2025-03-08
ndex: null
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP5496
- /instance/WP5496
- /instance/WP5496_r137728
revision: r137728
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP5496.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: '"Trastuzumab and pertuzumab inhibit HER2 signaling by binding to the
    extracellular domain of HER2. Lapatinib, neratinib, tucatinib, and pyrotinib inhibit
    HER signaling by binding to the intracellular tyrosine kinase domain of the Her
    family members.".  Source: Figure F1, https://pmc.ncbi.nlm.nih.gov/articles/PMC9281252/.  Derived
    from PFOCR, https://pfocr.wikipathways.org/figures/PMC9281252__12032_2022_1749_Fig1_HTML.html.'
  keywords:
  - AKT1
  - AKT2
  - AKT3
  - EGFR
  - ERBB2
  - ERBB3
  - ERBB4
  - HRAS
  - KRAS
  - Lapatinib
  - MAP2K1
  - MAP2K2
  - MAP2K3
  - MAP2K4
  - MAP2K5
  - MAP2K6
  - MAP2K7
  - MAPK1
  - MAPK3
  - NRAS
  - Neratinib
  - PIK3C2A
  - PIK3C2B
  - PIK3C2G
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R1
  - PIK3R2
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - Pertuzumab
  - Pyrotinib
  - RAF1
  - Trastuzumab
  - Tucatinib
  license: CC0
  name: Targeted therapy in breast cancer
seo: CreativeWork
title: Targeted therapy in breast cancer
wpid: WP5496
---